Intra-patient Dose Escalation Study of Sorafenib in Advanced Non-small Cell Lung Cancer

Inclusion Criteria:

* Histologically or cytologically confirmed, advanced (stage IIIB with pleural effusion, stage IV, or recurrent), kras mutation positive, non-small cell lung cancer (NSCLC)
* Measurable disease per RECIST criteria
* Patients must have received one + prior chemotherapy regimens for NSCLC
* Patients may have treated and clinically stable brain metastases
* Adequate bone marrow, liver and renal function
* Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to the start of treatment
* Women of childbearing potential and men must agree to use adequate contraception (barrier method of birth control) prior to study entry and for the duration of study participation, and for 3 months after last administration of sorafenib
* Patients must have the ability to understand and willingness to sign a written informed consent
* International normalized ratio(INR) \< 1.5 or prothrombin time/ partial thromboplastin time (PT/PTT) within normal limits

Exclusion Criteria:

* Prior exposure to a Ras pathway inhibitor
* Any other anti-tumor therapy within 3 weeks of enrollment
* Prior bevacizumab within the past 6 weeks
* An active secondary malignancy except non-melanoma skin cancer
* Cardiac disease: Congestive heart failure \> class II NYHA. Patients must not have unstable angina or new onset angina or myocardial infarction within the past 6 months
* Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy
* Uncontrolled hypertension, defined as systolic blood pressure \> 150mm Hg or diastolic pressure \> 90mm Hg, despite optical medical management
* Known human immunodeficiency virus (HIV) infection or chronic Hepatitis B or C
* Active clinically serious infection \> Common Terminology Criteria for Adverse Events (CTCAE) Grade 2
* Thrombolic or embolic events such as cerebrovascular accident including transient ischemic attack within the past 6 months
* Pulmonary hemorrhage/bleeding event \>/= CTCAE Grade 2 within 4 weeks of first dose of study drug
* Any other hemorrhage/bleeding event \>/= CTCAE Grade 3 within 4 weeks of first dose of study drug
* Serious non-healing wound, ulcer, or bone fracture
* Evidence or history of bleeding diathesis or coagulopathy
* Major surgery, open biopsy or significant traumatic injury within 4 weeks of first study drug
* Use of St. John's Wort or rifampin
* Known or suspected allergy to sorafenib or any agent given in the course of the trial
* Any condition that impairs patient's ability to swallow whole pills
* Any malabsorption problem